Photo taken from reveal-genomics.com
Sep 14, 2024, 09:48
Aleix Prat: Reveal Genomics Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial
Aleix Prat, Director of Cancer Institute and Blood Disorders at Hospital Clínic de Barcelona, shared on LinkedIn:
“REVEAL GENOMICS Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial
–HER2DX was evaluated in tumor samples from 214 patients with advanced HER2+ breast cancer treated with docetaxel, trastuzumab, and pertuzumab.
–The ERBB2 mRNA levels determined by HER2DX have shown a significant association with progression-free survival (PFS) and overall survival (OS).
–HER2DX is the world’s first diagnostic test formulated specifically for HER2+ breast cancer.”
Read Further.
Source: Aleix Prat/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 10:38
Dec 21, 2024, 10:35
Dec 21, 2024, 10:19
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37